HSBC downgraded Shanghai Fosun to Hold from Buy with a price target of HK$20, down from HK$40. The analyst cut estimates for 2023 due to the high base in 2022 with large COVID-19-related revenue and continued uncertainties such as Gland Pharma’s recovery.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>